J Immunol 2003 Feb 15;170(4):2179-85
Duplan V, Dutartre P, Mars LT, Liblau RS, Druet P, Saoudi A.
Institut National de la Sante et de la Recherche Medicale, Unite 563, Institut Federatif de Recherche 30, and Universite Paul Sabatier, Hopital Purpan, Toulouse, France. Laboratoires Fournier, Daix, France.
Experimental autoimmune encephalomyelitis (EAE) is a T cell-dependent autoimmune disease induced in susceptible animals by a single immunization with myelin basic protein (MBP).
LF 15-0195 is a novel immunosuppressor that has been shown to have a potent immunosuppressive effect in several pathological manifestations.
The purpose of this study was to investigate the effect of this drug on the induction and progression of established rat EAE and to dissect the mechanisms involved.
We show that LF 15-0195 administration at the time of MBP immunization reduces the incidence and severity of EAE in Lewis rats.
This drug also inhibits ongoing and passively induced EAE, indicating that LF 15-0195 affects already differentiated pathogenic lymphocytes.
Compared with lymph node cells from untreated rats, lymphocytes from MBP-immunized rats treated with LF 15-0195 proliferated equally well in response to MBP in vitro, while their ability to produce effector cytokines and to transfer EAE into syngeneic recipients was significantly reduced.
This phenomenon is stable and long-lasting.
Indeed, neither IL-12 nor repeated stimulation with naive APC and MBP in vitro rendered MBP-specific CD4 T cells from protected rats encephalitogenic.
In conclusion, LF 15-0195 treatment suppresses EAE by interfering with both the differentiation and effector functions of autoantigen-specific CD4 T cells.